Cetirizine

H1 antihistamine · also known as Zyrtec

Second-generation H1 antihistamine; blocks the H1 receptor and can still cause drowsiness despite a lower-sedation class profile.

How it relates to mast cells: Downstream of the mast cell
Types of studies cited: Randomised controlled trial
Approved in the US for: hay fever and upper respiratory allergy symptoms
Randomised trials in: chronic spontaneous urticaria
Also covers: Levocetirizine (Xyzal), Fexofenadine (Allegra), Loratadine (Claritin), Desloratadine (Clarinex), Bilastine, Bepotastine

What this relationship means: Acts after mast-cell mediators are released rather than stabilising the mast cell itself. This includes treatments that block mediator receptors, degrade a mediator, or oppose the physiology of an acute reaction. It describes where the intervention acts, not its clinical importance. A 2025 practical-management review places this at step 1 of the sequence it describes — described as the initial treatment, with second-generation agents prioritised over first. That is what the review reports, not a recommendation from this site.

Mechanism of action

Cetirizine occupies the histamine H1 receptor, preventing histamine already released from mast cells from producing its downstream effects — vasodilation, increased vascular permeability, pruritus, and sensory nerve stimulation. It acts on the mediator’s target rather than on the cell, so it does nothing to reduce degranulation itself.

Its randomised evidence comes from chronic spontaneous urticaria and allergic rhinitis rather than from MCAS. H1 blockade is the first step in the stepwise mediator-blockade approach described in the mast cell disease management literature.

Sources

Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria Peer-reviewed study 1996 PMID 8893110 · link checked 21 Aug 2026
Cetirizine hydrochloride US over-the-counter Drug Facts label Drug label · link checked 21 Aug 2026
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management Review article 2019 PMID 30961835 · link checked 20 Aug 2026
Pharmacotherapy of chronic spontaneous urticaria Review article 2013 PMID 24195758 · link checked 20 Aug 2026

What this evidence cannot establish

No randomised evidence in MCAS. H1 blockade is the conventional first step described in mast cell disease management, but that position rests on mechanism and consensus rather than trials in this population. The randomised results concern chronic urticaria, and the current consumer label warns that drowsiness may occur; neither fact establishes an MCAS outcome or predicts sedation for an individual.

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 21 Aug 2026